← Back to Clinical Trials
Recruiting NCT05877118

NCT05877118 Improving Availability of Intranasal Naloxone

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05877118
Status Recruiting
Phase
Sponsor Hartford Hospital
Condition Opioid Overdose
Study Type INTERVENTIONAL
Enrollment 84 participants
Start Date 2024-03-01
Primary Completion 2025-08-31

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Enhanced Overdose Education (EOE)Standard education

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 84 participants in total. It began in 2024-03-01 with a primary completion date of 2025-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

While there is a lifesaving medication called naloxone that can reverse the deadly effects of opioid overdose, patients often fail to fill the prescription at the pharmacy when it is prescribed. This is particularly concerning and true in those at the highest risk of death-those who end up in the emergency department for opioid overdose. The goal of this study is to compare the impact of different overdose education on naloxone prescription fill rates in opioid users being discharged from our hospital emergency department. You will receive either (a) written education about naloxone through their MyChart account, or (b) a concise one-page handout and 4-minute video clip reviewed with the participant and a support individual (family/friend) prior to discharge.

Eligibility Criteria

Inclusion Criteria: -Patients will be in the process of being discharged from Hartford Hospital ED with a naloxone kit prescription following opiate or opioid intoxication/poisoning, use of illicit opioids or prescription opioids, or opioid injection use-related conditions Exclusion Criteria: * Patient has previously received the standard naloxone kit education or has a known allergy to naloxone and/or kit constituents * Patient or support network does not speak English * Patient is in police custody * Patient is not being discharged home from the ED.

Contact & Investigator

Central Contact

Jimmy Choi, PsyD

✉ jimmy.choi@hhchealth.org

📞 860-545-7128

Principal Investigator

Jonathan C Allen, MD

PRINCIPAL INVESTIGATOR

Hartford HealthCare

Frequently Asked Questions

Who can join the NCT05877118 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Opioid Overdose. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05877118 currently recruiting?

Yes, NCT05877118 is actively recruiting participants. Contact the research team at jimmy.choi@hhchealth.org for enrollment information.

Where is the NCT05877118 trial being conducted?

This trial is being conducted at Hartford, United States, Hartford, United States.

Who is sponsoring the NCT05877118 clinical trial?

NCT05877118 is sponsored by Hartford Hospital. The principal investigator is Jonathan C Allen, MD at Hartford HealthCare. The trial plans to enroll 84 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology